Huile de CBD GW Pharma annonce ses résultats du quatrième trimestre et son objectif de chiffre d'affaires

Huile de CBD GW Pharma annonce ses résultats du quatrième trimestre et son objectif de chiffre d'affaires

maart 24, 2020 0 Door admin

Huile de CBD

Huile de CBD

Translating…

Click here for The Motley Fool’s resources on Coronavirus and the market.

Huile de CBD Sales of its CBD-derived epilepsy drug continue to surge.

Huile de CBD Mark Prvulovic

GW Pharmaceuticals (NASDAQ:GWPH) announced its fourth quarter and full year financial results Tuesday afternoon. Although the company ended up missing the earnings target set by Wall Street, GW Pharma did manage to handily beat analysts’ revenue expectations for the company.

Fourth quarter revenue came in at $109.1 million, a drastic increase from the $6.6 million reported a year ago. The vast majority of this figure came from sales of its CBD-derived drug, Epidiolex, which is used to treat two rare types of epilepsy in children known as Lennox-Gastaut syndrome and Dravet syndrome. The pharmaceutical company said that it sold $104.5 million worth of Epidiolex in the fourth quarter.

Huile de CBD A close-up of a cannabis plant.

Image source: Getty Images.

GW Pharma also reported a fourth quarter 2019 net loss of $24.9 million, which is a significant improvement from the $71.9 million net loss seen in fourth quarter 2018. The company still has $536.9 million in cash and cash equivalents as well, more than enough to fund itself as it looks to break a profit in 2020.

Huile de CBD Further details

Although GW Pharma ended up missing its earnings target, reporting a net loss per share of $0.07 in comparison to the net loss per share of $0.04 expected by analysts, revenue figures were well received. Wall Street had predicted around $105.1 million in sales for the quarter, a figure the company handily beat by $4 million.

Epidiolex holds the distinction of being the first CBD-derived drug to receive approval from the U.S. Food and Drug Administration. The decision, which was announced in June 2018, was a big deal for the industry, although the agency has yet to approve another cannabis drug since then.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.”>


Koop nu CBD Olie van de beste kwaliteit bij MHBioShop.com


Achetez maintenant de l’huile de CBD de la meilleure qualité chez HuileCBD.be


 

Lees meer